# A First-in-Human Study of PRL3-ZUMAB

> **NCT03191682** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 38 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** PRL3-ZUMAB

## Key facts

- **NCT ID:** NCT03191682
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-02-20
- **Primary completion:** 2027-02-20
- **Final completion:** 2027-02-20
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03191682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03191682, "A First-in-Human Study of PRL3-ZUMAB". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03191682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*